This has been an outstanding year for biotech stocks, and 2020 could be even better thanks to a slate of bonafide life-savers that hit pharmacy shelves months ahead of schedule.
The FDA approved dozens of drugs in 2019, but the agency rushed to greenlight these new cancer therapies much sooner than expected. Here's why they could be the industry's most successful product launches in 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,